Celgene Pays Acceleron $25M up front under anaemia drug partnership
This article was originally published in Scrip
Executive Summary
Celgene is paying privately held Acceleron Pharma $25 million up front under a deal to jointly develop and commercialise ACE-536, a ligand trap that inhibits members of the transforming growth factor- (TGF) beta "superfamily" involved in the late stages of erythropoiesis – the process of generating red blood cells – as a treatment for anaemia.
You may also be interested in...
Celgene Notches A Needed Win As Acceleron-Partnered Luspatercept Succeeds In MDS
Celgene delivers positive top-line Phase III results for a key pipeline drug as luspatercept reduces the need for blood transfusions in patients with myelodysplastic syndromes. Partner Acceleron's stock soars ahead of a detailed data presentation later this year.
Finance Watch: Genocea, Mateon Shift Strategies, Cut Jobs To Preserve Cash
Genocea shifts to preclinical neoantigen-based cancer vaccines rather than advance a Phase III-ready herpes program on its own and Mateon gives up on its lead drug as placebo outperforms. Also, Juno tops recent public company financings and new VC funds back early-stage firms.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.